The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Open accessAbstract
OBJECTIVE: To investigate the effects of exenatide on blood glucose, body weight and hepatic enzymes in patients with type 2 diabetes mellitus (T2DM) and concomitant non-alcoholic fatty liver disease (NAFLD). SUBJECTS AND METHODS: One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group. Patients were treated with exenatide and metformin, respectively, for 12 weeks. RESULTS: After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups. BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group. CONCLUSION: Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initially, the GLP-1 RAs’ superiority over other glucose-lowering medications that produce comparable glycemic control, including insulin and DPP-4 inhibitors, suggesting mechanisms unrelated to glucose reduction alone (13, 14, 39).”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is clear when compared to metformin (SMD = -0.95; 95% CI: -1.78 to -0.13), where exenatide showed better anti-inflammatory activity in spite of metformin’s proven pleiotropic advantages (13, 19, 38).”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to metformin and other medications, GLP-1 RAs dramatically decreased hepatic enzymes, liver fat content, and inflammatory markers in a number of trials that specifically investigated T2D patients with non-alcoholic fatty liver disease (NAFLD) (13, 28, 40).”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“it appears less effective than agents like exenatide in reducing hs-CRP (13).”
In the citing paper
“The authors showed that a 12-week treatment with exenatide was associated with a significant reduction in liver enzymes compared to treatment with metformin.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031 · cited 2×
“The prevalence of obesity and diabetes is increasing in China (2) and, thus, one may expect an increase in the incidence of NAFLD in T2DM in China.”
BackgroundRisk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Medical Consequences of Obesity
Bray, G. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0535 · Cited by 1,538 · cited 1×
“In clinical practice, we usually encounter patients that develop T2DM, obesity and NAFLD simultaneously (12,13).”
BackgroundPrimary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 8×
“Therefore, for T2DM patients with NAFLD, exenatide as a GLP-1 receptor agonist may not only reduce blood glucose and body weight, but also improve liver enzymes, attenuating NAFLD.”
BackgroundInfluentialKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Our new president—Jon I. Isenberg, M.D
Boland, C. R., & Yamada, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.24057 · Cited by 629
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Hepatology · doi:10.1002/hep.23623 · Cited by 564 · cited 1×
“The lack of benefit was because patients in the control group improved on diet, and metformin had little effect on liver histology (8).”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 1×
“However, in a murine model of fatty liver, exendin-4 significantly reduced glucose levels, improved insulin sensitivity, and reduced hepatic steatosis (10).”
Background
Cited by
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“2013 Fan [72] 117 T2DM and NAFLD patients Prospective randomized trial Exenatide vs metformin Yes Exenatide treatment results in significant improvement in liver enzymes compared with metformin.”
BackgroundResultInfluential
Metadata
- Authors
- Fan, H., Pan, Q., Xu, Y., & Yang, X.
- Affiliations
- Capital Medical University (CN)
- Venue
- Arquivos Brasileiros de Endocrinologia & Metabologia
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2013-12
- Volume
- 57
- Issue
- 9
- Pages
- 702-708
- ISSN
- 0004-2730 (ISSN-L)
- OpenAlex
- W1969489686
- Cited by
- 122
- References
- 26
- Citations by year
- 2026: 11 · 2025: 9 · 2024: 5 · 2023: 14 · 2022: 12 · 2021: 20 · 2020: 20 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 4 · 2015: 3 · 2014: 5
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Arquivos Brasileiros de Endocrinologia & Metabologia (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- exenatide, type 2 diabetes, non-alcoholic fatty liver disease, metformin, glycemic control, weight loss, liver enzymes, AST/ALT ratio, adiponectin, C-reactive protein, blood glucose
- MeSH terms
- Exenatide, Adult, Aged, Alanine Transaminase, Blood Glucose, Body Weight, C-Reactive Protein, Diabetes Mellitus, Type 2, Fatty Liver, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Time Factors, Venoms, Body Mass Index, Treatment Outcome, Waist-Hip Ratio, Adiponectin, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1590/s0004-27302013000900005
- The paper
- Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013). Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arquivos Brasileiros de Endocrinologia & Metabologia. https://doi.org/10.1590/s0004-27302013000900005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.